montanide isa51
Small moleculeexperimental
Clinical trial activity
56 trials · 44 clinical orgs · 0 marketing orgs
Phase 1
32
Phase 2
30
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 1998 (NCT00019396)
Timeline
Indications
Studied for
- Anemia, Refractory · Phase 1/Phase 2
- Bone Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Renal Cell · Phase 2
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Drugs, Investigational · Phase 1/Phase 2
- Eye Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Glioblastoma · Phase 2
- Glioma · Phase 1
- Gliosarcoma · Phase 2
- Hamartoma · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma, Follicular · Phase 1
- Melanoma · Phase 3
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 1
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neoplasms by Site · Phase 2
- Osteoarthritis, Knee · Phase 2
- Ovarian Neoplasms · Phase 1
- Pneumonia · Early Phase 1
- Primary Myelofibrosis · Phase 1
- Pulmonary Disease, Chronic Obstructive · Early Phase 1
- Rectal Neoplasms · Phase 1
- Sarcoma · Phase 1
- Skin Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Thrombocythemia, Essential · Phase 1
- Triple Negative Breast Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
Mechanism of action
- C-X-C chemokine receptor type 3ACTIVATOR
CXCR3 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- montanide isa51
- montanide isa 51
- montanide isa-51
- montanide isa 51 vg
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07169617 | Phase 2 | Feb 25, 2026 | National Cancer Institute (NCI), Northwestern University |
| NCT06605963 | Phase 2 | Dec 31, 2024 | Peptinov SAS |
| NCT06011772 | Early Phase 1 (Phase 1) | Dec 2, 2023 | State University of New York, Buffalo |
| NCT05876195 | N/A | Mar 1, 2023 | University of Oxford |
| NCT04447898 | Phase 1 | Sep 1, 2020 | Peptinov SAS |
| NCT04270149 | Phase 1 | May 1, 2020 | Duke University |
| NCT04298606 | Early Phase 1 (Phase 1) | Apr 1, 2020 | State University of New York, Buffalo |
| NCT04106115 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2019 | AstraZeneca, Shionogi, University of London |
| NCT04013672 | Phase 2 | Sep 29, 2019 | Case Western Reserve University, The Cleveland Clinic |
| NCT03929029 | Phase 1 | Jun 1, 2019 | Harvard University, National Cancer Institute (NCI) |
| NCT03939234 | Phase 2 | Apr 26, 2019 | IO Biotech, University of Copenhagen |
| NCT03893903 | Phase 1 | Oct 19, 2018 | German Cancer Research Center |
| NCT03617328 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2018 | University of Virginia |
| NCT03566446 | Phase 1 | Jun 20, 2018 | Center for Cancer Immune Therapy, Denmark, University of Copenhagen |
| NCT03381768 | Phase 1 | Dec 12, 2017 | University of Copenhagen |
| NCT02938442 | Phase 2 | Oct 1, 2017 | Hoosier Cancer Research Network |
| NCT03003195 | Phase 2 | Jun 1, 2017 | Hoosier Cancer Research Network |
| NCT02955290 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2016 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT02334735 | Phase 2 | Jul 1, 2015 | Cornell University, Icahn School of Medicine at Mount Sinai, Ludwig Institute for Cancer Research, Melanoma Research Alliance, New York University, Oncovir, Inc. |
| NCT02526316 | Phase 1 | Jun 1, 2015 | Oryx GmbH & Co. KG |
Showing 20 of 56 trials
Page 1 / 3
Organizations
Research & Development (44)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 23 | 12 | 4 | 1998 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 6 | 4 | 2 | 2003 |
| University of Virginia | Academic/Hospital | 6 | 5 | 3 | 2004 |
| National Institutes of Health (NIH) | Government | 4 | 0 | 1 | 1999 |
| State University of New York, Buffalo | Academic/Hospital | 4 | 4 | 2 | 2015 |
| University of Southern California | Academic/Hospital | 4 | 3 | 2 | 2001 |
| Cornell University | Academic/Hospital | 3 | 0 | 2 | 2003 |
| Hoosier Cancer Research Network | Academic/Hospital | 3 | 3 | 2 | 2011 |
| University of Copenhagen | Academic/Hospital | 3 | 3 | 2 | 2017 |
| Bristol-Myers Squibb | For profit | 2 | 0 | 1 | 2010 |
| Cancer Research Institute | Academic/Hospital | 2 | 0 | 2 | 2009 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 2 | 2 | 2 | 2009 |
| Medarex | For profit | 2 | 0 | 1 | 2010 |
| New York University | Academic/Hospital | 2 | 0 | 2 | 2006 |
| Oncovir, Inc. | For profit | 2 | 0 | 2 | 2012 |
| Peptinov SAS | For profit | 2 | 2 | 2 | 2020 |
| University of South Florida | Academic/Hospital | 2 | 2 | 1 | 2010 |
| University of Tokyo | Academic/Hospital | 2 | 1 | 2 | 2007 |
| University of Tuebingen | Academic/Hospital | 2 | 2 | 1 | 2004 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2019 |
44 organizations
Page 1 / 3